Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Read More…
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Phone972-8931-6233
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.60 million
Profitability
Miscellaneous
Employees80
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions
What is Foamix Pharmaceuticals' stock symbol?
Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."
How were Foamix Pharmaceuticals' earnings last quarter?
Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) posted its quarterly earnings data on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.07. Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 75.99%. View Foamix Pharmaceuticals' Earnings History.
When is Foamix Pharmaceuticals' next earnings date?
What price target have analysts set for FOMX?
5 analysts have issued 12-month price objectives for Foamix Pharmaceuticals' stock. Their predictions range from $10.00 to $30.00. On average, they anticipate Foamix Pharmaceuticals' share price to reach $15.40 in the next year. This suggests a possible upside of 423.8% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals.
What is the consensus analysts' recommendation for Foamix Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals.
What are Wall Street analysts saying about Foamix Pharmaceuticals stock?
Here are some recent quotes from research analysts about Foamix Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company's lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. " (10/22/2019)
- 2. Cantor Fitzgerald analysts commented, ": Post a solid quarter of execution and ahead of two potential launches for the company, we reiterate our OW rating and 12-month PT of $15 for FOMX shares. We continue to recommend FOMX as one of our top ideas for 2019 because we think its two de-risked assets, FMX101 and FMX103, as well as additional new opportunities that leverage FOMX’s technology are all underappreciated. Therefore, upward earnings revisions should drive the stock higher. FOMX’s earnings call is 8:30AM ET tomorrow." (5/7/2019)
Has Foamix Pharmaceuticals been receiving favorable news coverage?
News articles about FOMX stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Foamix Pharmaceuticals earned a media sentiment score of 0.6 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Foamix Pharmaceuticals.
Who are some of Foamix Pharmaceuticals' key competitors?
Some companies that are related to Foamix Pharmaceuticals include Canopy Rivers (RIV), Sundial Growers (SNDL), Chromadex (CDXC), True Drinks (TRUU), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO), Beleave (BE) and Beleave (BE).
What other stocks do shareholders of Foamix Pharmaceuticals own?
Who are Foamix Pharmaceuticals' key executives?
Foamix Pharmaceuticals' management team includes the folowing people:
- Mr. David T. Domzalski, CEO & Director (Age 52)
- Mr. Ilan Hadar M.B.A., MBA, CFO & Country Mang. (Age 50)
- Ms. Mutya Harsch, Gen. Counsel & Chief Legal Officer (Age 44)
- Dr. Darrell S. Rigel M.D., MS, Consultant (Age 69)
- Dr. Iain A. Stuart, Chief R&D Officer (Age 46)
Who are Foamix Pharmaceuticals' major shareholders?
Foamix Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Crow Point Partners LLC (0.14%). Company insiders that own Foamix Pharmaceuticals stock include Aharon Schwartz, Alvin D Howard, Anna Kazanchyan, David Domzalski, Iain Stuart, Ilan Hadar, Matthew T Wiley, Meir Eini, Mutya Harsch, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.
Which major investors are buying Foamix Pharmaceuticals stock?
FOMX stock was bought by a variety of institutional investors in the last quarter, including Crow Point Partners LLC. Company insiders that have bought Foamix Pharmaceuticals stock in the last two years include Aharon Schwartz and Matthew T Wiley. View Insider Buying and Selling for Foamix Pharmaceuticals.
How do I buy shares of Foamix Pharmaceuticals?
Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Foamix Pharmaceuticals' stock price today?
One share of FOMX stock can currently be purchased for approximately $2.94.
How big of a company is Foamix Pharmaceuticals?
Foamix Pharmaceuticals has a market capitalization of $179.34 million and generates $3.60 million in revenue each year. The specialty pharmaceutical company earns $-74,160,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. Foamix Pharmaceuticals employs 80 workers across the globe.View Additional Information About Foamix Pharmaceuticals.
What is Foamix Pharmaceuticals' official website?
How can I contact Foamix Pharmaceuticals?
Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]
MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
